指南与共识神经肿瘤神经重症

SNO与EANO实践指南更新:新诊断脑肿瘤患者的抗癫痫预防用药

SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.
指南 / 共识 · Neuro Oncol · 2021-01-01

推荐对新诊断未发癫痫的脑肿瘤患者不处方抗癫痫药以降低癫痫风险(A级);围手术期用药证据不足(C级);不推荐为延长生存而用丙戊酸或左乙拉西坦(C级);可考虑左乙拉西坦减少副作用(C级);肿瘤位置、组织学等特征不足以指导预防用药(U级)。

要点

  • 未发癫痫的新诊断脑肿瘤患者不应预防性使用抗癫痫药(A级推荐)。
  • 围手术期预防用药证据不足,不推荐常规使用(C级)。
  • 可优先考虑左乙拉西坦而非旧抗癫痫药以减少副作用(C级)。

核心结论

  • 对新诊断未发癫痫的脑肿瘤患者,不推荐处方抗癫痫药以降低癫痫风险(A级)。
  • 围手术期预防用药、以延长生存为目的用药、依据肿瘤特征决策均证据不足。

研究设计与样本

  • 遵循2017年AAN方法学,系统检索PubMed、EMBASE、Cochrane和Web of Science数据库。
  • 研究多为II级和III级,I级研究有限,AAN确认了指南价值。

关键数值与推荐

  • 未发癫痫的新诊断脑肿瘤患者:不应处方抗癫痫药以降低癫痫风险(A级)。
  • 脑肿瘤手术患者:围手术期或术后预防用药证据不足(C级)。
  • 不推荐为延长无进展生存或总生存而使用丙戊酸或左乙拉西坦(C级)。
  • 可考虑左乙拉西坦替代旧抗癫痫药以减少副作用(C级)。
  • 肿瘤位置、组织学、分级、分子/影像特征不足以指导预防用药决策(U级)。

临床怎么用

  • 对未发癫痫的新诊断脑肿瘤患者,不常规预防性使用抗癫痫药。
  • 围手术期不常规预防用药,需个体化评估。
  • 如需用药,可优先考虑左乙拉西坦以减少副作用。
  • 不应仅根据肿瘤位置、组织学等特征决定预防用药。

局限性

  • 纳入研究多为II级和III级证据,高级别I级研究有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To update the 2000 American Academy of Neurology (AAN) practice parameter on anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. METHODS: Following the 2017 AAN methodologies, a systematic literature review utilizing PubMed, EMBASE Library, Cochrane, and Web of Science databases was performed. The studies were rated based on the AAN therapeutic or causation classification of evidence (class I-IV). RESULTS: Thirty-seven articles were selected for final analysis. There were limited high-level, class I studies and mostly class II and III studies. The AAN affirmed the value of these guidelines. RECOMMENDATIONS: In patients with newly diagnosed brain tumors who have not had a seizure, clinicians should not prescribe antiepileptic drugs (AEDs) to reduce the risk of seizures (level A). In brain tumor patients undergoing surgery, there is insufficient evidence to recommend prescribing AEDs to reduce the risk of seizures in the peri- or postoperative period (level C). There is insufficient evidence to support prescribing valproic acid or levetiracetam with the intent to prolong progression-free or overall survival (level C). Physicians may consider the use of levetiracetam over older AEDs to reduce side effects (level C). There is insufficient evidence to support using tumor location, histology, grade, molecular/imaging features when deciding whether or not to prescribe prophylactic AEDs (level U).

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Walbert T, Harrison RA, Schiff D, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol. 2021. PMID: 34174071. doi:10.1093/neuonc/noab152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。